Eyevensys, a developer of gene therapies for ophthalmic diseases, announced today that it raised $12 million in a Series B plus funding round. The funding, led by Korea Investment Partners, also includes existing investors who will join the round and support the accelerated development of Eyevensys’ EYS809 program for treating wet age-related macular degeneration (AMD) […]
Eyevensys
Ocular continues personnel shakeup with new CMO | Personnel Moves – Sept. 13, 2017
After Ocular Therapeutix‘s (NSDQ:OCUL) founder & CEO, Amar Swahney, stepped down earlier this year, pharma executive Antony Mattessich stepped in to assume the corner office. He signaled some major changes to the company’s business strategy in a call with analysts last month, including an attempt to ‘aggressively seek new partnerships’ and ‘enhance [the company’s] credibility’. As […]
First uveitis patient treated with Eyevensys’ electro-transfection system
Private biotech Eyevensys said today that it treated the 1st patient in a first-in-human phase I/II trial of its lead candidate, EYS606, for the treatment of non-infectious uveitis. The patient was treated in Paris at the Cochin Institute using the company’s EyeCET technology. The EyeCET platform is an electro-transfection injection system that delivers non-viral plasmids to encode […]
Eyevensys wins approval to start clinical development of EyeCET platform
Private biotech Eyevensys said today that it won approval from the UK Medicines and Healthcare Products Regulatory Agency to advance its EyeCET platform into clinical development. The company’s EyeCET platform uses an electro-transfection injection system to deliver non-viral plasmids that encode for disease-specific therapeutic proteins in the ciliary muscle of the eye. Eyevensys’ lead product […]
